Introgen`s Adenoviral Vector Demonstrates Safety in Phase II Study Biosafety Data Presented at American Society of Gene Therapy Meeting
(PR Newswire)...is a replication-impaired adenoviral vector carrying the human p53 tumor suppressor gene.......additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......candidate, INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I clinical development....- Jun 01 7:30 PM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010601/daf011.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines